Gyre Therapeutics Inc (GYRE) said Thursday that it priced its underwritten public offering of about 2.2 million shares of its common stock at $9 per share for expected gross proceeds of about $20 million.
The company also granted the underwriters a 30-day option to buy up to an additional 333,333 shares. The offering is expected to close on or about Tuesday.
The company said it plans to use the net proceeds, along with its existing cash and cash equivalents and cash flows from operations, to advance its phase 2 clinical trial of F351 in the US, for research and development, manufacturing and scale-up, as well as for working capital and general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.